How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | KPV | Melanotan I |
|---|---|---|
| ✓ | — | |
| — | ✓ |
What These Compounds Share
No direct target, secondary target, pathway tag, or research area is shared by all selected compounds — see Key Differences below. This reflects the structured data as recorded, not an absence of any conceivable relationship.
Key Differences
Compound Detail
KPV
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Tripeptide · 3 amino acids · Lys-Pro-Val · Derived fragment of α-MSH
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (1) →
Supports treating KPV's anti-inflammatory effects as potentially receptor-independent rather than a conventional melanocortin agonist action.
Supports: mechanism_summary, key_differentiator
Melanotan I
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Synthetic peptide · Synthetic analogue
Tap a target above for a plain-language explanation.
Measured directly in a 3-participant human PK trial comparing IV, oral and SC administration -- no detectable drug after oral dosing (not orally bioavailable); this is a very small sample.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (1) →
The paper itself equates "[Nle4-D-Phe7]-alpha-MSH(4-13)" directly with "melanotan-I (MT-I)" -- confirming this is the literature name for the same sequence later marketed as afamelanotide/Scenesse. No detectable drug after oral dosing (not orally bioavailable). SC fully bioavailable vs IV; beta-phase half-life 0.8-1.7h; clearance 0.12-0.19 L/kg/h. Noticeable tanning after IV/SC dosing, peaking at 1 week, still present 3 weeks post-regimen. Very small sample (n=3).
Supports: human_half_life, canonical_name, research_limitations
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist